First Time Loading...

bluebird bio Inc
NASDAQ:BLUE

Watchlist Manager
bluebird bio Inc Logo
bluebird bio Inc
NASDAQ:BLUE
Watchlist
Price: 1.28 USD -6.23% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

BLUE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. [ Read More ]

The intrinsic value of one BLUE stock under the Base Case scenario is 10.59 USD. Compared to the current market price of 1.28 USD, bluebird bio Inc is Undervalued by 88%.

Key Points:
BLUE Intrinsic Value
Base Case
10.59 USD
Undervaluation 88%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
bluebird bio Inc

Backtest BLUE Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BLUE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of bluebird bio Inc's business.

What risks and challenges
does bluebird bio Inc face in the near future?

Summarize the latest earnings report
of bluebird bio Inc.

Provide P/E
for bluebird bio Inc and its competitors.

Financials

Balance Sheet Decomposition
bluebird bio Inc

Current Assets 247.1m
Cash & Short-Term Investments 174.2m
Receivables 23m
Other Current Assets 49.9m
Non-Current Assets 366.5m
PP&E 304.7m
Intangibles 11m
Other Non-Current Assets 50.8m
Current Liabilities 159m
Accounts Payable 19.9m
Accrued Liabilities 121.5m
Other Current Liabilities 17.6m
Non-Current Liabilities 232.1m
Other Non-Current Liabilities 232.1m
Efficiency

Earnings Waterfall
bluebird bio Inc

Revenue
21.8m USD
Cost of Revenue
-24.1m USD
Gross Profit
-2.3m USD
Operating Expenses
-328.8m USD
Operating Income
-331.1m USD
Other Expenses
239.9m USD
Net Income
-91.2m USD

Free Cash Flow Analysis
bluebird bio Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

BLUE Profitability Score
Profitability Due Diligence

bluebird bio Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Declining ROE
17/100
Profitability
Score

bluebird bio Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

BLUE Solvency Score
Solvency Due Diligence

bluebird bio Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
50/100
Solvency
Score

bluebird bio Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BLUE Price Targets Summary
bluebird bio Inc

Wall Street analysts forecast BLUE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BLUE is 5.44 USD with a low forecast of 1.03 USD and a high forecast of 13.65 USD.

Lowest
Price Target
1.03 USD
20% Downside
Average
Price Target
5.44 USD
325% Upside
Highest
Price Target
13.65 USD
966% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BLUE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BLUE Price
bluebird bio Inc

1M 1M
-8%
6M 6M
-58%
1Y 1Y
-61%
3Y 3Y
-94%
5Y 5Y
-99%
10Y 10Y
-91%
Annual Price Range
1.28
52w Low
0.9052
52w High
5.03
Price Metrics
Average Annual Return -47.82%
Standard Deviation of Annual Returns 11.9%
Max Drawdown -99%
Shares Statistics
Market Capitalization 246.7m USD
Shares Outstanding 192 742 000
Percentage of Shares Shorted 18.91%

BLUE Return Decomposition
Main factors of price return

What is price return decomposition?

BLUE News

Other Videos

Last Important Events
bluebird bio Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
bluebird bio Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

bluebird bio Inc Logo
bluebird bio Inc

Country

United States of America

Industry

Biotechnology

Market Cap

246.7m USD

Dividend Yield

0%

Description

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 518 full-time employees. The company went IPO on 2013-06-19. The firm is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s programs in genetic diseases include betibeglogene autotemcel (beti-cel) as a treatment for transfusion-dependent B-thalassemia (TDT); LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). The company develops LentiGlobin gene therapy for patients with SCD, a hereditary blood disorder resulting from a mutation in the b-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. The beti-cel is marketed as ZYNTEGLO for the treatment of adult and adolescent patients with TDT in the European Union. Its product candidate also include SKYSONA for the treatment of patients with CALD in the European Union, Iceland, Liechtenstein and Norway.

Contact

MASSACHUSETTS
Cambridge
60 Binney St
+13394999300.0
http://www.bluebirdbio.com

IPO

2013-06-19

Employees

518

Officers

President, CEO & Director
Mr. Andrew Obenshain
Chief Commercial Officer & COO
Mr. Thomas J. Klima
Chief Medical Officer
Mr. Richard A. Colvin M.D., Ph.D.
CFO, Principal Accounting Officer & Treasurer
Mr. Christopher Krawtschuk CPA
Chief Legal & Business Officer and Secretary
Mr. Joseph D. Vittiglio Esq., J.D.
Head of Corporate Communications
Jess Rowlands
Show More
Chief People Officer
Ms. Andrea Walton
Senior Vice President of Technical Development & Operations
Mr. Kasra Kasraian
Senior Vice President of Quality
Mr. Scott Shoemaker
Senior Vice President of External Affairs
Ms. Sarah Alspach
Show Less

See Also

Discover More
What is the Intrinsic Value of one BLUE stock?

The intrinsic value of one BLUE stock under the Base Case scenario is 10.59 USD.

Is BLUE stock undervalued or overvalued?

Compared to the current market price of 1.28 USD, bluebird bio Inc is Undervalued by 88%.